BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 30337929)

  • 21. Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.
    Pfeffermann LM; Pfirrmann V; Huenecke S; Bremm M; Bonig H; Kvasnicka HM; Klingebiel T; Bader P; Rettinger E
    Cytotherapy; 2018 Jun; 20(6):839-850. PubMed ID: 29754771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel method for detection of virus-specific CD41+ T cells indicates a decreased EBV-specific CD4+ T cell response in untreated HIV-infected subjects.
    Piriou ER; van Dort K; Nanlohy NM; van Oers MH; Miedema F; van Baarle D
    Eur J Immunol; 2005 Mar; 35(3):796-805. PubMed ID: 15724243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Memory CD8(+) T cells elicited by HIV-1 lipopeptide vaccines display similar phenotypic profiles but differences in term of magnitude and multifunctionality compared with FLU- or EBV-specific memory T cells in humans.
    Figueiredo S; Charmeteau B; Surenaud M; Salmon D; Launay O; Guillet JG; Hosmalin A; Gahery H
    Vaccine; 2014 Jan; 32(4):492-501. PubMed ID: 24291199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
    Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune escape by Epstein-Barr virus associated malignancies.
    Münz C; Moormann A
    Semin Cancer Biol; 2008 Dec; 18(6):381-7. PubMed ID: 18996483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.
    Gallot G; Hamidou MA; Clémenceau B; Gaschet J; Tiberghien P; Ferrand C; Vivien R; Barbarot S; Coste-Burel M; Moreau A; Vié H
    Clin Immunol; 2006 Apr; 119(1):79-86. PubMed ID: 16386957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive Tumors.
    Eom HS; Choi BK; Lee Y; Lee H; Yun T; Kim YH; Lee JJ; Kwon BS
    J Immunother; 2016 Apr; 39(3):140-8. PubMed ID: 26938947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cross-reactivity influences changes in human influenza A virus and Epstein Barr virus specific CD8 memory T cell receptor alpha and beta repertoires between young and old.
    Clark F; Gil A; Thapa I; Aslan N; Ghersi D; Selin LK
    Front Immunol; 2022; 13():1011935. PubMed ID: 36923729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of Epstein-Barr virus- and HIV-specific CD27- CD8+ T cells is associated with progression to viral disease in HIV-infection.
    van Baarle D; Kostense S; Hovenkamp E; Ogg G; Nanlohy N; Callan MF; Dukers NH; McMichael AJ; van Oers MH; Miedema F
    AIDS; 2002 Oct; 16(15):2001-11. PubMed ID: 12370498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
    Leong IT; Fernandes BJ; Mock D
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy.
    Piriou E; Jansen CA; van Dort K; De Cuyper I; Nanlohy NM; Lange JM; van Oers MH; Miedema F; van Baarle D
    J Immunol; 2005 Aug; 175(3):2010-7. PubMed ID: 16034146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selection of a diverse TCR repertoire in response to an Epstein-Barr virus-encoded transactivator protein BZLF1 by CD8+ cytotoxic T lymphocytes during primary and persistent infection.
    Silins SL; Cross SM; Elliott SL; Pye SJ; Burrows JM; Moss DJ; Misko IS
    Int Immunol; 1997 Nov; 9(11):1745-55. PubMed ID: 9418135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longitudinal analysis of frequency and reactivity of Epstein-Barr virus-specific T lymphocytes and their association with intermittent viral reactivation.
    Vogl BA; Fagin U; Nerbas L; Schlenke P; Lamprecht P; Jabs WJ
    J Med Virol; 2012 Jan; 84(1):119-31. PubMed ID: 22095540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV infection confers distinct mechanisms in severe drug eruption: Endogenous virus activation with aberrant Th2/Th1 and CD8
    Tang JT; Li YY; Zhang Y; Liu J; Guan W; Wang RR; He LP; Zhang JB; Kuang YQ
    Clin Exp Pharmacol Physiol; 2020 Jun; 47(6):1005-1013. PubMed ID: 31991490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of T cell receptor Vbeta repertoires in HIV type 1-infected SCID-hu mice.
    Boldt-Houle DM; Jamieson BD; Aldrovandi GM; Rinaldo CR; Ehrlich GD; Zack JA
    AIDS Res Hum Retroviruses; 1997 Jan; 13(2):125-34. PubMed ID: 9007198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A skewed distribution and increased PD-1+Vβ+CD4+/CD8+ T cells in patients with acute myeloid leukemia.
    Huang J; Tan J; Chen Y; Huang S; Xu L; Zhang Y; Lu Y; Yu Z; Chen S; Li Y
    J Leukoc Biol; 2019 Sep; 106(3):725-732. PubMed ID: 31136687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD4+ T cell responses in the immune control against latent infection by Epstein-Barr virus.
    Paludan C; Münz C
    Curr Mol Med; 2003 Jun; 3(4):341-7. PubMed ID: 12776989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exhausted cytotoxic control of Epstein-Barr virus in human lupus.
    Larsen M; Sauce D; Deback C; Arnaud L; Mathian A; Miyara M; Boutolleau D; Parizot C; Dorgham K; Papagno L; Appay V; Amoura Z; Gorochov G
    PLoS Pathog; 2011 Oct; 7(10):e1002328. PubMed ID: 22028659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic Epstein-Barr virus-related hepatitis in immunocompetent patients.
    Petrova M; Muhtarova M; Nikolova M; Magaev S; Taskov H; Nikolovska D; Krastev Z
    World J Gastroenterol; 2006 Sep; 12(35):5711-6. PubMed ID: 17007027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD8 TCR β chain repertoire expansions and deletions are related with immunologic markers in HIV-1-infected patients during treatment interruption.
    González-Serna A; Abad-Fernández M; Soriano-Sarabia N; Leal M; Vallejo A
    J Clin Virol; 2013 Dec; 58(4):703-9. PubMed ID: 24210957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.